Cargando…
A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function
BACKGROUND: The Holt–Oram syndrome (HOS) is an autosomal dominant disorder affecting 1/100.000 live births. It is defined by upper limb anomalies and congenital heart defects with variable severity. We describe a dramatic phenotype of a male, 15‐month‐old patient being investigated for strict diagno...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023941/ https://www.ncbi.nlm.nih.gov/pubmed/27652283 http://dx.doi.org/10.1002/mgg3.234 |
_version_ | 1782453715754549248 |
---|---|
author | Dreßen, Martina Lahm, Harald Lahm, Armin Wolf, Klaudia Doppler, Stefanie Deutsch, Marcus‐André Cleuziou, Julie Pabst von Ohain, Jelena Schön, Patric Ewert, Peter Malcic, Ivan Lange, Rüdiger Krane, Markus |
author_facet | Dreßen, Martina Lahm, Harald Lahm, Armin Wolf, Klaudia Doppler, Stefanie Deutsch, Marcus‐André Cleuziou, Julie Pabst von Ohain, Jelena Schön, Patric Ewert, Peter Malcic, Ivan Lange, Rüdiger Krane, Markus |
author_sort | Dreßen, Martina |
collection | PubMed |
description | BACKGROUND: The Holt–Oram syndrome (HOS) is an autosomal dominant disorder affecting 1/100.000 live births. It is defined by upper limb anomalies and congenital heart defects with variable severity. We describe a dramatic phenotype of a male, 15‐month‐old patient being investigated for strict diagnostic criteria of HOS. METHODS AND RESULTS: Genetic analysis revealed a so far unpublished TBX5 mutation, which occurs de novo in the patient with healthy parents. TBX5 belongs to the large family of T‐box transcription factors playing major roles in morphogenesis and cell‐type specification. The mutation located in the DNA‐binding domain at position 920 (C→A) leads to an amino acid change at position 85 (proline → threonine). Three‐dimensional analysis of the protein structure predicted a cis to trans change in the respective peptide bond, thereby probably provoking major conformational and functional alterations of the protein. The p.Pro85Thr mutation showed a dramatically reduced activation (97%) of the NPPA promoter in luciferase assays and failed to induce NPPA expression in HEK 293 cells compared to wild‐type TBX5 protein. The mutation did not interfere with the nuclear localization of the protein. CONCLUSION: These results suggest that the dramatic functional alteration of the p.Pro85Thr mutation leads to the distinctive phenotype of the patient. |
format | Online Article Text |
id | pubmed-5023941 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50239412016-09-20 A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function Dreßen, Martina Lahm, Harald Lahm, Armin Wolf, Klaudia Doppler, Stefanie Deutsch, Marcus‐André Cleuziou, Julie Pabst von Ohain, Jelena Schön, Patric Ewert, Peter Malcic, Ivan Lange, Rüdiger Krane, Markus Mol Genet Genomic Med Original Articles BACKGROUND: The Holt–Oram syndrome (HOS) is an autosomal dominant disorder affecting 1/100.000 live births. It is defined by upper limb anomalies and congenital heart defects with variable severity. We describe a dramatic phenotype of a male, 15‐month‐old patient being investigated for strict diagnostic criteria of HOS. METHODS AND RESULTS: Genetic analysis revealed a so far unpublished TBX5 mutation, which occurs de novo in the patient with healthy parents. TBX5 belongs to the large family of T‐box transcription factors playing major roles in morphogenesis and cell‐type specification. The mutation located in the DNA‐binding domain at position 920 (C→A) leads to an amino acid change at position 85 (proline → threonine). Three‐dimensional analysis of the protein structure predicted a cis to trans change in the respective peptide bond, thereby probably provoking major conformational and functional alterations of the protein. The p.Pro85Thr mutation showed a dramatically reduced activation (97%) of the NPPA promoter in luciferase assays and failed to induce NPPA expression in HEK 293 cells compared to wild‐type TBX5 protein. The mutation did not interfere with the nuclear localization of the protein. CONCLUSION: These results suggest that the dramatic functional alteration of the p.Pro85Thr mutation leads to the distinctive phenotype of the patient. John Wiley and Sons Inc. 2016-07-14 /pmc/articles/PMC5023941/ /pubmed/27652283 http://dx.doi.org/10.1002/mgg3.234 Text en © 2016 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Dreßen, Martina Lahm, Harald Lahm, Armin Wolf, Klaudia Doppler, Stefanie Deutsch, Marcus‐André Cleuziou, Julie Pabst von Ohain, Jelena Schön, Patric Ewert, Peter Malcic, Ivan Lange, Rüdiger Krane, Markus A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function |
title | A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function |
title_full | A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function |
title_fullStr | A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function |
title_full_unstemmed | A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function |
title_short | A novel de novo TBX5 mutation in a patient with Holt–Oram syndrome leading to a dramatically reduced biological function |
title_sort | novel de novo tbx5 mutation in a patient with holt–oram syndrome leading to a dramatically reduced biological function |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023941/ https://www.ncbi.nlm.nih.gov/pubmed/27652283 http://dx.doi.org/10.1002/mgg3.234 |
work_keys_str_mv | AT dreßenmartina anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT lahmharald anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT lahmarmin anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT wolfklaudia anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT dopplerstefanie anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT deutschmarcusandre anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT cleuzioujulie anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT pabstvonohainjelena anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT schonpatric anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT ewertpeter anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT malcicivan anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT langerudiger anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT kranemarkus anoveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT dreßenmartina noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT lahmharald noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT lahmarmin noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT wolfklaudia noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT dopplerstefanie noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT deutschmarcusandre noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT cleuzioujulie noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT pabstvonohainjelena noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT schonpatric noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT ewertpeter noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT malcicivan noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT langerudiger noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction AT kranemarkus noveldenovotbx5mutationinapatientwithholtoramsyndromeleadingtoadramaticallyreducedbiologicalfunction |